• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    PepGen Inc. - Common Stock (NQ: PEPG )

    8.830 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 8.830
    Bid (Size) 3.540 (2)
    Ask (Size) 10.62 (7)
    Prev. Close 8.830
    Today's Range 8.830 - 8.830
    52wk Range 3.720 - 19.30
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
    From PepGen Inc.
    Via Business Wire
    PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
    From PepGen Inc.
    Via Business Wire

    Performance

    YTD
    +24.54%
    +24.54%
    1 Month
    +2.79%
    +2.79%
    3 Month
    -50.62%
    -50.62%
    6 Month
    -37.51%
    -37.51%
    1 Year
    +43.81%
    +43.81%

    More News

    Read More
    PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    PEPG Stock Earnings: PepGen Misses EPS for Q2 2024
    Via InvestorPlace
    PEPG Stock Earnings: PepGen Beats EPS for Q1 2024
    Via InvestorPlace
    PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
    Via InvestorPlace
    PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
    From PepGen Inc.
    Via Business Wire
    PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher
    Via Benzinga
    Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
    From PepGen Inc.
    Via Business Wire
    PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
    From PepGen Inc.
    Via Business Wire
    PepGen Announces Executive Team Promotions
    From PepGen Inc.
    Via Business Wire
    PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
    From PepGen Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Insiders Buying GameStop And 2 Other Stocks
    Via Benzinga
    PepGen to Participate in Upcoming Investor Conferences
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
    From PepGen Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
    From PepGen Inc.
    Via GlobeNewswire
    PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
    From PepGen Inc.
    Via GlobeNewswire
    Over $37M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.